Blog

Can This Stock Live Up to the Hype? Wall Street Weighs In on AI-Powered Healthcare

TFT-admin | July 10, 2024

Tempus AI Inc. (TEM), a recent entrant into the public market, has caught the eye of Wall Street analysts who are impressed by the company’s application of artificial intelligence (AI) in the field of cancer diagnostics. Despite a volatile stock price since its June IPO, several leading analysts have issued bullish calls on Tempus, citing […]

Xeris Biopharma: Undervalued Gem with Promising Pipeline and Licensing Deals on the Horizon

TipsForTraders | June 4, 2024

Xeris Biopharma (XERS) might not be a household name on Wall Street, but for investors seeking a compelling combination of steady revenue growth, a promising drug development pipeline, and potential for lucrative licensing deals, XERS deserves a closer look. Despite its strong fundamentals and significant growth potential, XERS has remained under the radar, trading far […]

Biden administration to impose inflation penalties on dozens of drugs

reuters | December 14, 2023

By Andrea Shalal BETHESDA, Md. (Reuters) -The Biden administration said on Thursday it had identified 48 drugs in the Medicare program whose prices rose quicker than inflation during the fourth quarter of the year and may require their makers to pay rebates. President Joe Biden’s signature Inflation Reduction Act (IRA) includes a provision to penalize […]

Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies

reuters | December 1, 2023

By Patrick Wingrove (Reuters) -Novo Nordisk said on Thursday it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%. The Danish drugmaker said it found impurities in all the drugs […]

Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug

reuters | November 21, 2023

By Brendan Pierson (Reuters) -Texas Attorney General Ken Paxton accused Pfizer and its supplier Tris Pharma of providing children’s ADHD medicine that it knew might be ineffective to the state’s Medicaid insurance program for low-income people, in a lawsuit unsealed on Monday. The lawsuit, filed in Harrison County, Texas District Court, alleges that Pfizer and […]

Retail investors crowd into Eli Lilly after weight-loss drug approval

reuters | November 17, 2023

By Bhanvi Satija and Amruta Khandekar (Reuters) – Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, […]

Wegovy’s heart benefits due to more than weight loss, Novo says

reuters | November 13, 2023

By Patrick Wingrove PHILADELPHIA (Reuters) -Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Early data from the Danish drugmaker’s Select trial released in August demonstrated that Wegovy, […]

Next Page »